AAV Gene Therapy for ALS Muscle-Specific CNTF Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for amyotrophic lateral sclerosis (ALS) are ineffective when initiated late in the disease process and often cause systemic side effects due to the need for high doses of systemic CNTF injections, which limit the amount that can be administered.
Innovation Solution
The use of adeno-associated virus (AAV) vectors to introduce genes that increase ciliary neurotrophic factor receptor (CNTFRα), cardiotrophin-like cytokine factor 1 (CLC), and cytokine receptor-like factor 1 (CLF) into skeletal muscle, enhancing endogenous neuroprotective mechanisms to inhibit ALS progression without systemic side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic CNTF injections are administered to treat ALS, then CNTF receptor signaling is enhanced and motor neurons are protected, but systemic side effects occur that limit the amount of CNTF that can be administered
Solution Approach 1:
The invention segments the therapeutic approach by using AAV vectors to deliver CNTF gene specifically to skeletal muscle tissue, rather than systemic administration. This localizes the therapeutic effect to the neuromuscular junction where it is most needed, while avoiding widespread systemic exposure that causes side effects.
Solution Approach 2:
The invention applies local quality by concentrating CNTF expression in skeletal muscle tissue through targeted AAV delivery. This creates high local concentration of CNTF at the neuromuscular junction without producing high systemic levels, thereby achieving therapeutic effect while minimizing systemic side effects.
2Reliability
If high doses of systemic CNTF are administered to achieve therapeutic effect, then motor neuron protection is enhanced, but systemic side effects increase and limit further administration
Solution Approach 1:
The invention divides the delivery system into targeted AAV vectors that specifically infect skeletal muscle cells, concentrating the therapeutic effect locally without requiring high systemic doses. This segmentation allows effective motor neuron protection through localized CNTF expression.
Solution Approach 2:
The invention creates local high concentration of CNTF in skeletal muscle tissue through targeted gene delivery, achieving effective motor neuron protection at the neuromuscular junction without producing the systemic side effects that would limit dose escalation.
3Ease of operation
If ALS treatment is initiated late in the disease process, then treatment is more clinically relevant, but effectiveness of treatment is reduced
Solution Approach 1:
The invention employs preliminary action by using AAV vectors that establish persistent, long-term CNTF expression in skeletal muscle. This sustained expression provides continuous neuroprotective effect that can slow disease progression even when treatment is initiated at later stages, making the therapy clinically applicable while maintaining effectiveness.
Data Source
Figure 1A~1C
Figure 2A~2E
Figure 3A~3C
AI summary
A method for treating a subject suffering from a motor neuron degenerative disorder is provided herein, the method including: administering to the subject one or more modified adeno-associated virus (AAV) gene delivery vectors packaging a recombinant AAV (rAVV)-based genome, wherein each AAV vector is engineered to include a cDNA insert selected from a ciliary neutrophic factor receptor alpha (CNTFRa) cDNA insert, a cardiotrophin-like cytokine factor 1 (CLC) cDNA insert, and a cytokine receptor-like factor 1 (CLF) cDNA insert. Also provided are pharmaceutical compositions including one or more modified AAV gene delivery vectors, each AAV vector packaging a rAAV genome engineered to include (i) a cDNA insert selected from CNTFRa, CLC, and CLF; and (ii) a promoter; and a pharmaceutically acceptable excipient.